BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages 80-85

  Akashi Tanaka, Sadako ^a   Watanabe, Chie ^a   Takamaru, Tomoko ^a   Kuwayama, Takashi ^a   Ikeda, Murasaki ^a   Ohyama, Hiroto ^a   Mori, Miki ^a   Yoshida, Reiko ^a   Hashimoto, Rikako ^a   Terumasa, Sawada ^a   Enokido, Katsutoshi ^a   Hirota, Yuko ^a   Okuyama, Hiromi ^a   Nakamura, Seigo ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Multiplex ligation dependent probe amplification; Platinum salts; Predictive marker; Prognostic marker; Taxane resistance

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT THERAPY; CARCINOMA, DUCTAL, BREAST; DRUG RESISTANCE; GENETICS; HETEROZYGOTE; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, DUCTAL, BREAST; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE; HUMANS; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PROGNOSIS; RETROSPECTIVE STUDIES; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84920471424     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.08.003     Document Type: Article

References (28)

1. B.D. Lehmann, J.A. Bauer, and X. Chen Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies J Clin Invest 121 2011 2750 2767
2. P. Cortazar, L. Zhang, and M. Untch Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 2014 164 172
3. G. von Minckwitz, M. Untch, and J.U. Blohmer Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 2012 1796 1804
4. H. Iwata, N. Sato, and N. Masuda Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer Jpn J Clin Oncol 41 2011 867 875
5. T. Shien, M. Yoshida, and T. Hojo Clinicopathologic features of primary breast cancer resisting primary systemic therapy Jpn J Breast Cancer 23 2008 49 53
6. G. Von Minckwitz, A. Schneeweiss, and C. Salat Addition of Carboplatin Beneficial in Neoadjuvant Treatment of Triple-NegativeBreast Cancer J Clin Oncol (Proc ASCO) 2014 1004
7. Sikov WN, Berry DA, Perou CM, et al. The impact of addition of carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel followed by dose-dense AC on pathologic complete response rate in triple -negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol Published Ahead of Print on August 4, 2014 as http://dx.doi.org/10.1200/JCO.2014.57.0572.
8. F. Petrelli, A. Coinu, and K. Borgonovo The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis Breast Cancer Res Treat 144 2014 223 232
9. M. Liu, Q.G. Mo, and C.Y. Wei Platinum-based chemotherapy in triple-negative breast cancer: a meta-analysis Oncol Lett 5 2013 983 991
10. N. Turner, A. Tutt, and A. Ashworth Hallmarks of "BRCAness" in sporadic cancers Nat Rev Cancer 4 2004 814 819
11. M.A. Vollebergh, E.H. Lips, and P.M. Nederlof An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients Ann Oncol 22 2011 1561 1570
12. J.M. Lee, J.A. Ledermann, and E.C. Kohn PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies Ann Oncol 25 2014 32 40
13. A.M. Oonk, C. van Rijn, and M.M. Smits Clinical correlates of "BRCAness" in triple-negative breast cancer of patients receiving adjuvant chemotherapy Ann Oncol 23 2012 2301 2305
14. P. Chalasani, and R. Livingston Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review Oncologist 18 2013 909 916
15. E.H. Lips, N. Laddach, and S.P. Savola Quantitative copy number analysis by multiplex ligation-dependent probe amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness Breast Cancer Res 13 2011 R107
16. S. Rottenberg, A.O. Nygren, and M. Pajic Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer Proc Natl Acad Sci U S A 104 2007 12117 12122
17. M. Kriege, A. Jager, and M.J. Hooning The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers Cancer 118 2012 899 907
18. S. Rummel, E. Varner, and C.D. Shriver Evaluation of BRCA1 mutations in an unselected patient population with triple-negative breast cancer Breast Cancer Res Treat 137 2013 119 125
19. E.A. Eisenhauer, J. Bogaerts, and L.H. Schwartz New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
20. R. Shigenaga, and S. Akashi-Tanaka [Comparison among Japanese general rules for clinical and pathological recording of breast cancer, 16th ed and UICC TNM classification, 7th ed] Nihon Rinsho 70 suppl 7 2012 191 194
21. Y. Kanda Investigation of the freely available easy-to-use software "EZR" for medical statistics Bone Marrow Transplant 48 2013 452 458
22. E.H. Lips, L. Mulder, and A. Oonk Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers Br J Cancer 108 2013 2172 2177
23. M. Sung, and P. Giannakakou BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling Oncogene 33 2014 1418 1428
24. S. Lafarge, V. Sylvain, and M. Ferrara Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway Oncogene 20 2001 6597 6606
25. C. Chabalier, C. Lamare, and C. Racca BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance Cell Cycle 5 2006 1001 1007
26. J. Kurebayashi, Y. Yamamoto, and M. Kurosumi Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes Anticancer Res 26 2006 695 701
27. Telli M, Jensen KC, Kurian AW, et al. PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer ASCO proceedings. 2013, Abstract PD 09-04.
28. S. Paluch-Shimon, E. Friedman, and R. Berger Does pathologic complete response predict for outcome in BRCA mutation carriers with triple-negative breast cancer? J Clin Oncol 32 suppl 2014 5s (abstract 1023)